137 related articles for article (PubMed ID: 38614068)
1. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
3. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
4. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract][Full Text] [Related]
6. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract][Full Text] [Related]
7. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Sotorasib for previously treated colorectal cancers with KRAS
Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
[TBL] [Abstract][Full Text] [Related]
10. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced
Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC
JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866
[TBL] [Abstract][Full Text] [Related]
14. KRAS
Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
[TBL] [Abstract][Full Text] [Related]
17. Sotorasib: First Approval.
Blair HA
Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
[TBL] [Abstract][Full Text] [Related]
18. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
19. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
20. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
Soulières D; Gelmon KA
J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060
[No Abstract] [Full Text] [Related]
[Next] [New Search]